NIH Reporter #2037T

CSP #2037T, Veterans Affairs Learning Health System Initiative to Assess Novel Screening vs. Usual Care and Treatment With Apixaban vs. Rivaroxaban in Veterans With Atrial Fibrillation (VALIANT-AF-T)

A 7-year VA clinical trial comparing the safety and efficacy of apixaban versus rivaroxaban in preventing strokes in veterans with atrial fibrillation, involving about 10,000 patients.

Description

This study will compare two anticoagulants (apixaban and rivaroxaban) used in the Department of Veterans Affairs to prevent strokes in patients with atrial fibrillation. The trial will enroll about 10,000 VA patients nationally and measure rates of stroke, major bleeding, or death between the two drugs over about 7 years. It is a phase 4, pragmatic, point of care, parallel group, unblinded randomized trial embedded in VA clinical care.

View original record